Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KCNAB1 antisense RNA 2 (KCNAB1-AS2) is a long non-coding RNA (lncRNA) transcribed antisense to the KCNAB1 gene. It does not encode a protein but may play a role in the regulation of the KCNAB1 gene, which encodes a regulatory beta subunit of voltage-gated potassium channels. Antisense lncRNAs such as KCNAB1-AS2 are involved in diverse mechanisms of gene regulation at the transcriptional and post-transcriptional levels, often through modulation of chromatin structure, recruitment of transcriptional machinery, and interaction with the sense transcript. The specific biological function, disease relevance, and druggability of KCNAB1-AS2 remain largely uncharacterized, and there is currently no evidence to support its role as a validated therapeutic target or its involvement in disease states as a biomarker or through direct pharmacological modulation[5][4][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KCNAB1 antisense RNA 2 (KCNAB1-AS2).